1.. Introduction {#S1}
================

Muscle stem cells (MuSCs), which reside between the sarcolemma and basal lamina, are required for the maintenance of adult muscle and muscle regeneration after injury ([@R1]; [@R2]). MuSCs exist in a tightly regulated quiescent state ([@R2]). MuSC activation and proliferation is induced in response to increased mechanical load or to muscle injury ([@R3]; [@R4]). Upon activation, MuSCs progress through the myogenic lineage until fusion with damaged myofibers occurs and muscle repair is achieved ([@R3]). The activation and differentiation of MuSCs has been extensively studied leading to the identification of sequentially expressed markers specific to each step of this process. Pax7, a transcription factor expressed by quiescent and early-activated MuSCs, is required for their functionality in homeostatic and regenerating conditions. Indeed, lack of Pax7 expression in MuSCs *in vivo* results in the absence of muscle regeneration following injury ([@R5]; [@R6]). Upon activation, expression of MyoD, a transcription factor responsible for early commitment, promotes MuSC entry into the cell cycle ([@R7]). Finally, myogenin is activated, inducing terminal differentiation of MuSCs that can fuse together to form new myofibers or fuse with the existing myofibers.

Studies of MuSCs autonomous properties rely mainly on the use of fluorescence-activated cell sorting (FACS). Isolation of MuSCs has been described in mouse, human, pig, and cow ([@R8]; [@R9]; [@R10]; [@R11]; [@R12]; [@R13]). A wide array of cell surface proteins have been reported as positive markers for MuSC identification and isolation, namely β1-integrin (CD29), CXCR4 (CD184), VCAM-1 (CD106), NCAM (CD56), α-7 integrin, CD34, tetraspanin (CD82), and CD318. Negative selection markers are conserved among laboratories and different mammalian species and include CD45 (lymphocytes), CD31 (endothelial cells), CD11b (macrophages), and Sca1 (fibro-adi-pogenic progenitors). Despite the extensive knowledge of MuSC identification markers and the broad spectrum of protocols employed for their isolation among multiple species, purification of MuSCs from rat has never been reported.

The rat model has been extensively used in skeletal muscle research ([@R14]). Rat, compared to other rodents, better recapitulates human muscle in architecture, physiology, and anatomy, making it a better model to study skeletal muscles. Muscle architecture (macroscopic arrangement of muscle fibers), which is fundamental for *in vivo* muscle function, has been shown to be similar between rats and humans, when compared to other animal models ([@R15]). Comparative studies of abdominal muscles revealed a high degree of similarity within the same muscle groups between rat and human. The major architectural parameters (physiological cross sectional area, operational sarcomere length, and fiber orientation) were comparable, despite differences in body size and muscle mass ([@R16]). Additionally, studies of the female pelvic floor muscles showed that rats, compared to other commonly used laboratory animals, such as rabbit and mouse, were the closest to humans in terms of muscle design ([@R17]). Moreover, the architectural difference index of rat pelvic floor muscles, which quantifies how closely rat muscle architecture resembles human muscle architecture, was comparable to that of non-human primates ([@R16]; [@R18]). Furthermore, rat and human *in vivo* response to exercise shows similar qualitative and quantitative changes in plasma volume and blood biochemical parameters ([@R19]). Additionally, the rat physiology is closer to human physiology than mouse is, making rat a widely employed preclinical model for toxicology and safety studies ([@R20]). Indeed, like in human, the rat genome contains genes involved in protein breakdown and detection and detoxification of chemicals that have been lost in the mouse genome ([@R21]). Finally, rats are 10-fold larger than mice, which facilitates a wider variety of experimental procedures, collection of larger samples, and study of rare cell populations or low abundance molecules. The larger size of the rat also enables multiple concomitant measurements in a single animal, thus, reducing the number of animals needed.

Given that the rat model is widely used in studies focused on skeletal muscles ([@R22]), we aimed to develop and validate an efficient and reliable protocol for MuSC isolation from the rat. The central role of MuSCs in the maintenance of muscle homeostasis and regeneration makes isolation and study of MuSC autonomous properties of fundamental importance. Here, we describe for the first time a method for isolation of rat MuSCs via FACS that relies on a single positive marker (VCAM-1 (CD106)) for identification of this cell population.

2.. Materials and methods {#S2}
=========================

2.1.. Animals {#S3}
-------------

Female 3-months old Sprague-Dawley rats (Envigo) were euthanized via CO2 inhalation followed by thoracotomy. Hind limb muscles (tibialis anterior (TA), gastrocnemius (GAS) and quadriceps), diaphragm (DIA), and pelvic floor muscles (coccygeus (C), iliocaudalis (ICa), and pubocaudalis (PCa)) were harvested. The University of California San Diego Institutional Animal Care and Use Committee approved all study procedures.

2.2.. Cell isolation {#S4}
--------------------

Muscle stem cells (MuSCs) were isolated as described in [@R23] with minor modifications ([@R23]). Cell isolation was performed using Ham's F-10 supplemented with 10% horse serum. TA, GAS, DIA, C, ICa, and PCa were individually minced and incubated in 700 units/ml collagenase type II solution for 1.5 h and collagenase and dispase II solution (100 units/mL and 2 units/mL, respectively) for 30 min. Tissue was then passed through a 20 G needle and a 70 µm nylon filter. Antibody incubation was performed in 1 mL volume for 1 h.

The positive markers used to identify the MuSCs were CD29, CD56, and CD106. The negative selection markers used to identify hematopoietic and endothelial cells were CD45, CD11b, and CD31. Antibody titration was performed with LSR Fortessa (BD Biosciences, USA). Multiple antibody concentrations were tested: 0.5, 1, 1.5, 2, 3 µg per 10^6^ cells for the individual positive and negative markers; and 0.1, 0.2, 0.3, 0.4, 0.5 µg per 10^6^ cells for the negative markers in combination. Proper antibody concentration was chosen using the stain index (*FI*: fluorescent intensity): $$n\, index = \frac{\left( {FI\, positive\, population - FI\, negative\, population} \right)}{2\, x\, standarad\, deviation\, negative\, population}$$ MuSCs were isolated with FACSAria II (BD Biosciences, USA) cell sorter employing three different protocols. Protocol 1: Lin^−^ / CD106^+^; Protocol 2: Lin^−^ / CD56^+^ / CD29^+^; and Protocol 3: Lin^−^ / CD106^+^ / CD29^+^ (Lin^−^: CD45^−^ / CD11b^−^ / CD31^−^). We performed 3 separate isolations for each muscle analyzed.

2.3.. Cell culture {#S5}
------------------

Cells were plated (2500 cells/well) in laminin coated 96-well plates in growth media (40% DMEM (Dulbecco's modified Eagle's medium), 40% Ham's F-10, 20% fetal bovine serum, 1% Pen/Strep (penicillin/streptomycin), 25 ng/mL basic fibroblast growth factor.) Cells were fixed 2, 12, 72, and 120 h after isolation to determine expression of myogenic markers. Myogenic differentiation was induced on 10000 cells 12 h after isolation, employing differentiation media (DMEM, 2% horse serum, 1% Pen/Strep) as previously described ([@R24]), and assessed 72 h later.

2.4.. Immunostaining {#S6}
--------------------

Frozen tissue sections were fixed with 4% paraformaldehyde (PFA), washed in PBS (phosphate-buffered saline), and incubated for 1 h with blocking buffer (20% goat serum + 0.3% Triton X-100 in PBS) before overnight incubation with laminin primary antibody (1:200) in blocking buffer. After 3 PBS washes, the slides were incubated for 2 h with secondary antibody (Alexa Fluor 546 goat anti-rabbit IgG) in blocking buffer. After another PBS wash, the slides were post-fixed with 4% PFA, washed again and immersed in boiling antigen unmasking solution for 15 min. Slides were then washed in PBS and incubated with blocking buffer (1 h), followed by Pax7 antibody (1:100) overnight. After 3 PBS washes, the slides were incubated for 2 h with secondary antibody (Alexa Fluor 488 goat anti-mouse IgG) in blocking buffer. Cultured cells were fixed with 4% PFA, washed in PBS, and incubated with blocking buffer (1 h), followed by Pax7 (1:100), MyoD (1:100), Myogenin (1:100), or MyHC (1:100) overnight. Secondary antibodies (Alexa 546 goat anti-mouse IgG and Alexa 488 goat anti-mouse IgG) were incubated at 1:250 dilutions in blocking buffer. Nuclei were identified with DAPI (1:1000).

2.5.. RNA isolation and analysis {#S7}
--------------------------------

RNA isolation was performed on freshly isolated cells with miRNeasy Micro kit per manufacturer protocol. QIAxpert was employed for RNA quantification. cDNA was obtained with SuperScript VILO cDNA Synthesis kit, and SYBR green PCR master Mix was used for qRT-PCR.

2.6.. Imaging {#S8}
-------------

Imaging was carried out using the Keyence BZX710 microscope (Keyence, Japan). Quantification was performed on 5--8 unmodified images per well (10X magnification) with Adobe Photoshop CS4 and ImageJ.

2.7.. Statistical analysis {#S9}
--------------------------

Data were compared between groups using one- or two-way ANOVA, followed by pairwise comparisons with Tukey's range test when appropriate, with significance set to 5%. All statistical analyses were performed with Prism 8.

[Key resources table](#T1){ref-type="table"} containing vendor and catalog number for all commercial products used in this study is provided.

3.. Results {#S10}
===========

We first assessed *in situ* localization of MuSCs in the rat tibialis anterior (TA). Visual assessment of \~300 MuSCs indicated that all Pax7^+^ cells localized under the basal lamina with none present in the interstitial space, similar to mouse MuSCs ([Fig. 1](#F1){ref-type="fig"}) ([@R25]). Quantification of MuSCs in rat TA revealed an average of 10 Pax7^+^ cells per mm^2^. Our results are comparable to mouse, where the density of MuSCs ranges from 5 to 20 cells/mm^2^ ([Fig. 1](#F1){ref-type="fig"}) ([@R26]; [@R27]; [@R28]).

3.1.. Determination of reliable positive markers for rat MuSC isolation {#S11}
-----------------------------------------------------------------------

To isolate a highly enriched MuSC population, we identified commercially available antibodies suitable in rat and tested them on pooled preparations of TA, GAS, and quadriceps to determine antibody binding specificity and optimal concentrations ([Figure S1](#SD1){ref-type="supplementary-material"}). First, CD106, CD56, and CD29 antibodies were titrated through flow cytometry to confirm the expression of each marker in the muscles. Analyses were performed on the LSR Fortessa where non-treated controls were compared to cells treated with one of the five progressively increasing antibody concentrations (0.5, 1, 1.5, 2, and 3 µg per 10^6^ cells) ([Figs. S1A](#SD1){ref-type="supplementary-material"}--[S1C](#SD1){ref-type="supplementary-material"}). Based on the stain index, the optimal concentration for all antibodies was 1.5 µg per 10^6^ cells. Similarly, we titrated antibodies for the negative selection markers: CD31, CD45, and CD11b. Each antibody was tested separately ([Figs. S1D](#SD1){ref-type="supplementary-material"}--[S1F](#SD1){ref-type="supplementary-material"}) to assess binding specificity, and in combination to ensure that simultaneous use of multiple antibodies did not cause signal saturation ([Fig. S1G](#SD1){ref-type="supplementary-material"}). Optimal staining was achieved with 0.3 µg per 10^6^ cells for each antibody.

Guided by protocols from other models, we tested three isolation strategies in the rat TA. Protocol 1 relied on CD106 as the only positive marker. In Protocols 2 and 3, cells were concurrently stained for CD56 and CD29 or CD106 and CD29, respectively ([Fig. 2A](#F2){ref-type="fig"}). We used single color and fluorescence minus one (FMO) controls to determine the gating system ([Figure S1K](#SD1){ref-type="supplementary-material"}--[M](#SD1){ref-type="supplementary-material"}). Using forward and side scatter parameters independent of fluorescent signal, we first excluded cellular debris and cell clusters ([Fig. 2B](#F2){ref-type="fig"}--[D](#F2){ref-type="fig"}, three top plots). For Protocol 1, we used DAPI negative staining to identify live cells. Within the live cell population, we then determined which lineage negative cells (CD31^−^/CD45^−^/CD11b^−^, Lin^−^) expressed CD106 ([Fig. 2B](#F2){ref-type="fig"}). Employing Protocol 1, we identified a single putative MuSC population (P1). For Protocols 2 and 3, we utilized the lack of negative selection markers and DAPI expression to identify live Lin^−^ cells, coupled with the expression of both positive markers to discern the presumed MuSC populations. Interestingly, expression of the CD56 marker (Protocol 2) was detectable in samples prepared from pooled hind limb muscle homogenate, but not in samples derived from TA alone, suggesting that CD56 is not conserved among different muscles. We, therefore, excluded CD56 from further experiments. In Protocol 2, we observed a clear separation of two cell populations based on CD29 expression ([Fig. 2C](#F2){ref-type="fig"}). Using Protocol 3, we also identified two cells populations: one positive for both CD29 and CD106 and the other positive only for CD29 ([Fig. 2D](#F2){ref-type="fig"}). We went on to further examine the following subpopulations: CD29^High^ (P2) and CD29^Low^ (P2b) identified using Protocol 2, and CD106^+^/CD29^+^ (P3) and CD106^−^/CD29^+^ (P3b) identified using Protocol 3 ([Fig. 2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}).

3.2.. CD106 is a valid marker for isolation of rat MuSCs from tibialis anterior muscle {#S12}
--------------------------------------------------------------------------------------

To test cell identity and myogenic commitment of the 5 cell populations (P1, P2, P2b, P3, and P3b) described above, we isolated cells from TA using BD Biosciences FACSAria II cell sorter. First, we compared the percentage of putative MuSCs sorted using our three different protocols ([Fig. S2A](#SD1){ref-type="supplementary-material"}). Protocols 1 and 3 yielded 1.6% for P1 (CD106^+^) and P3 (CD106^+^/CD29^+^) populations, which was significantly lower than 6.5% putative MuSCs isolated employing Protocol 2 (CD29^High^) ([Figure S2A](#SD1){ref-type="supplementary-material"}). P2b (CD29^Low^) constituted 9.3% and P3b (CD106^−^/CD29^+^) 12.4% of the original sorted population ([Fig. S2A](#SD1){ref-type="supplementary-material"}). After isolation, cells were plated and fixed either 2 or 12 h later to assess cell identity or cultured in growth conditions for 3 and 5 days to determine their myogenic potential ([Fig. 3A](#F3){ref-type="fig"}). Expression of Pax7 in freshly isolated P1, P2, and P3 populations was \~90% and 80% 2 and 12 h after isolation, respectively ([Fig. 3B](#F3){ref-type="fig"}). In contrast, only 20% of P2b (CD29^Low^) and 50% of P3b (CD106^−^/CD29^+^) populations expressed Pax7 2 h after isolation ([Figure S2B](#SD1){ref-type="supplementary-material"}). These results suggest that P1, P2, and P3 populations represent a highly enriched MuSCs population, whereas, only up to a half of the P2b and P3b cells were potential MuSCs. Thus, using CD29^Low^ or CD106^−^/CD29^+^ precludes efficient isolation of a highly enriched population.

To assess the ability of the isolated cells to progress through myogenic lineage, cells cultured in growth media for 3 and 5 days were assessed for the expression of MyoD and myogenin, respectively. Around 80% of P1, P2, and P3 populations expressed MyoD, whereas less than 40% of the P2b and P3b cells expressed MyoD ([Fig. 3C](#F3){ref-type="fig"} and [S2C](#SD1){ref-type="supplementary-material"}). Moreover, 20% of P1, P2, and P3 cells expressed myogenin, while myogenin was detected in less than 1% of P2b and P3b populations ([Fig. 3D](#F3){ref-type="fig"} and [S2D](#SD1){ref-type="supplementary-material"}). Taken together, these data show that only CD106^+^ (P1), CD29^High^ (P2), and CD106^+^/CD29^+^ (P3) cells express high levels of Pax7 and are capable of efficiently progressing through the myogenic lineage *in vitro*.

To determine the ability of P1, P2, and P3 populations to complete myogenic differentiation, we placed cells in serum-deprived media for 3 days. Myosin heavy chain (MyHC), a marker of terminal differentiation, was used to calculate the differentiation index ((nuclei of MyHC^+^ cells/total nuclei number)\*100) ([Fig. 3E](#F3){ref-type="fig"}). P1 and P3 differentiation index was over 60%, compared to only 40% in the P2 population ([Fig. 3F](#F3){ref-type="fig"}). Moreover, P2 cells demonstrated a lower ability to fuse, evidenced by sparse appearance of the myotubes relative to the P1 and P3 populations. ([Fig. S2F](#SD1){ref-type="supplementary-material"}). Consistent with their low ability to undergo myogenic commitment, the differentiation index of P2b and P3b cells was less than 2% ([Fig. S2E](#SD1){ref-type="supplementary-material"}). These results indicate that Protocols 1 and 3 accurately identify rat MuSCs capable of myogenic commitment and terminal differentiation.

Despite high expression of Pax7, P2 (CD29^High^) cells were not capable of efficient differentiation or fusion compared to P1 and P3 populations. To investigate potential mechanisms underlying these differences, we analyzed myogenic gene expression by qRT-PCR on cells freshly isolated using all three protocols ([Fig. 3G](#F3){ref-type="fig"}). A significant increase in myogenin expression was observed in the P2 population relative to P1 and P3 populations. Moreover, a trend towards reduced Pax7 gene expression was noted in P2 compared to P1 and P3 cells. These results suggest that P2 cells are more committed than P1 and P3 populations. Given that Protocol 2 led to the isolation of less undifferentiated cells that could not undergo efficient myogenic differentiation ([Fig. 3F](#F3){ref-type="fig"} and [G](#F3){ref-type="fig"}), this protocol was excluded from further analyses.

While Protocol 1 relies solely on CD106 as a positive isolation marker, Protocol 3 depends on two positive markers: CD106 and CD29. Importantly, cells obtained from both protocols did not differ phenotypically, indicating that both protocols yield comparable MuSC populations. Given fiscal and technical advantages of employing a single positive marker for the identification of MuSCs, we focused on validating Protocol 1 in five additional rat muscles.

3.3.. MuSCs can be efficiently isolated from a broad range of rat skeletal muscles employing CD106 as a single positive marker {#S13}
------------------------------------------------------------------------------------------------------------------------------

To validate our selected protocol, we tested its reliability and efficiency in isolating MuSCs from other rat skeletal muscles, specifically GAS, DIA, and the individual pelvic floor muscles (C, ICa, and PCa). To enhance population separation during isolation, which increases MuSC yield, we first optimized the gating for Protocol 1 ([Fig. 4A](#F4){ref-type="fig"}). Based on MuSC size, determined during the initial experiments ([Fig. 2B](#F2){ref-type="fig"}), we applied a gate to select for live small cells. Further gates were progressively designed to define single cell populations, Lin^−^ cells, and CD106^+^ cells. This new gating system was reproducible among all muscles evaluated, leading to a consistent isolation of 2--3% of MuSC from the initial number of cells and improving upon 1.6% yield from the previous gating system ([Fig. 4B](#F4){ref-type="fig"}, [Figure S2A](#SD1){ref-type="supplementary-material"} and [Figure S3A](#SD1){ref-type="supplementary-material"}). Upon isolation, cells were plated in growth media for 2 h, fixed, and assessed for Pax7 expression to evaluate their identity ([Fig. 4C](#F4){ref-type="fig"}). Consistent with the results obtained for TA, \~90% of cells isolated from all other muscles expressed Pax7 ([Fig. 4D](#F4){ref-type="fig"}). Moreover, high expression of MyoD and myogenin was present when the cells were placed in culture for 3 and 5 days, respectively ([Figs. S3B](#SD1){ref-type="supplementary-material"}--[S3E](#SD1){ref-type="supplementary-material"}). Cells placed in serum-deprived media for 3 days exhibited a differentiation index between 70 and 80% ([Fig. 4E](#F4){ref-type="fig"} and [F](#F4){ref-type="fig"}). These results confirm that Protocol 1 can be reliably employed in different muscles in the rat model for isolation of a highly enriched MuSC population capable of myogenic commitment and terminal differentiation.

4.. Discussion {#S14}
==============

The positive markers selected for our studies were based on the existing literature and antibody availability for rat, and included vascular cell adhesion molecule (VCAM-1, CD106), neural cell adhesion molecule (NCAM, CD56), and β1-integrin (CD29). CD106 is a trans-membrane protein in the immunoglobulin superfamily that has been successfully used for isolation of mouse MuSCs ([@R8]). Importantly, expression of this protein in quiescent cells is required for maintenance of their basal function and prevention of premature lineage progression ([@R29]). The current study demonstrates, for the first time, that CD106 is a reliable marker for the isolation of a highly enriched MuSC population from various rat skeletal muscles. Indeed, CD106^+^/CD45^−^/CD31^−^/CD11b^−^ cells express Pax7 at high levels and are capable of myogenic commitment and full differentiation into myotubes.

CD56 has been mainly described as a marker of quiescent human MuSCs ([@R9]; [@R10]). In rodents, expression of this marker has been associated only with MuSCs activated in response to either differentiation stimuli *in vitro* or denervation *in vivo* ([@R30]; [@R31]). While we observed CD56 expression when analyzing whole muscle cell preparations ([Fig. S1C](#SD1){ref-type="supplementary-material"}), expression was not found in Lin^−^ gated cells during the sorting process. CD56 is likely expressed in the neuromuscular junctions and not in the MuSCs that we want to isolate ([@R31]). CD29, has been previously used for the isolation of MuSCs from mouse, pig, and cow ([@R11], [@R12]; [@R13]). It is a member of the integrin family and interacts with collagen, fibronectin, and laminin depending on its heterodimer binding partner ([@R32]). It is highly expressed in MuSCs and is necessary for maintenance of quiescence in homeostatic conditions and cell proliferation after injury ([@R33]). Moreover, in myoblasts, CD29 is indispensable for cell fusion ([@R34]). In contrast to the previous studies, we found that CD29^High^ cells have reduced Pax7 and increased myogenin gene expression ([Fig. 3G](#F3){ref-type="fig"}), and fuse less. The antibody used for the isolation of cells in Protocol 2 is specific for α~4~β~1~ integrin immunogen, preferentially selecting for cells expressing the α~4~ subunit in association with CD29. The resultant cell population is therefore enriched for α~4~β~1~ integrin, while being depleted off α~5~-α~7~β~1~ integrins. Previous work suggests that the interplay between integrin heterodimers is essential for proper myogenic differentiation and fusion ([@R35]). We believe that the lack of integrin heterodimer heterogeneity in P2 cells accounts for the phenotype observed in our experiments.

Currently, the majority of MuSC studies are performed in a mouse, owing to the opportunities for genetic manipulation of this model ([@R36]). However, the small size of these animals significantly limits the amount of muscle tissue, which in turn restricts the number of MuSCs that can be isolated making it hard to perform experiments demanding large cell numbers, such as RNA or ChIP sequencing. The insufficient yield of MuSCs from small mouse muscles necessitates pooling of different muscles from the same animal or pooling of the same muscle type from multiple animals ([@R37]; [@R38]). Pooling different specimens masks the intrinsic variability of different muscles or individual organisms, potentially affecting results and their interpretation. Moreover, given recent evidence that MuSCs are highly heterogeneous, maintaining muscle and animal identity in future studies could enhance our understanding of diverse MuSC populations ([@R7]; [@R39]). Using the rat model (10 times larger than a mouse) can help scientists circumvent these limitations and expand the existing studies to smaller muscles previously set aside due to technical constraints. For instance, the regenerative potential of MuSCs from extensor digitorum longus and soleus, small muscles that differ with respect to MuSC number and fiber phenotype, have never been directly compared ([@R25], [@R40]).

Using our optimized protocol, we obtain a proportion of the sorted cells similar to the mouse ([Fig. 4A](#F4){ref-type="fig"} and [S3A](#SD1){ref-type="supplementary-material"}) ([@R8]). Our *in situ* evaluations ([Fig. 1](#F1){ref-type="fig"}) showed an average of 10 Pax7^+^ cells per mm^2^, which is also comparable to the number of MuSCs per mm^2^ in mouse ([@R26]; [@R27]; [@R28]). Given the above and the larger size of the rat muscles, one can isolate a greater number of MuSCs from the rat. This opens new avenues for investigations focused on the autonomous function of MuSCs derived from small-sized muscles. Larger animal models, such as non-human primates, pig, or cow, would, of course, allow isolation of an even greater number of MuSCs. However, these models are costly relative to the rat, and numerous constraints related to housing and handling of these species exist.

5.. Conclusions {#S15}
===============

In conclusion, a single positive selection marker can be used to reliably isolate MuSCs from a variety of rat skeletal muscles. The use of the rat model for the study of MuSCs offers a major advantage to the skeletal muscle research field, enabling investigations of single muscles of different sizes and individual animals.
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![MuSCs localization. MuSCs identified by Pax7 expression in the rat Tibialis Anterior (TA) muscle. Left: low magnification image of TA (scale bar 50 µm). Center: Zoomed in images of Pax7+ cell (scale bar 25 µm). Right: quantification of Pax7+ cells.](nihms-1068079-f0001){#F1}

![Gating approach for cell isolation protocols. (A) Experimental design for panels B--D. (TA: Tibialis Anterior). FACS plots for the gating approach used in protocols 1 (B), 2 (C), and 3 (D).](nihms-1068079-f0002){#F2}

![Phenotypic validation of cell populations isolated using three protocols. (A) Experimental design for panels B-D (TA: Tibialis Anterior; IF: immunofluorescence; GM: Growth Media). (B) Left: Pax7 expression in freshly isolated cells (scale bar 50 µm); right: quantification of Pax7+ cells plated for 2 and 12 h after isolation. (C) Left: MyoD expression in cultured cells (scale bar 50 µm); right: quantification of MyoD+ cells in culture for 72 h. (D) Left: myogenin expression in cultured cells (scale bar 100 µm); right: quantification of Myogenin+ cells in culture for 120 h. (E) Experimental design for panel F. (DM: Differentiation Media). (F) Left: myosin heavy chain (MyHC) expression in differentiated cells (scale bar 50 µm); right: quantification of MyHC + nuclei after 72 h in DM. (G) Quantitative real time PCR in freshly isolated cells for myogenic genes (Pax7, MyoD, Myogenin), comparing P1, P2, and P3 populations. All data are normalized to P1 population.](nihms-1068079-f0003){#F3}

![Phenotypic validation of cells isolated using Protocol 1 in gastrocnemius, diaphragm, and pelvic floor muscles. (A) FACS plots for the optimized gating for protocol 1. (GAS: Gastrocnemius; DIA: Diaphragm; C: coccygeus; ICa: iliocaudalis; PCa: pubocaudalis; GM: Growth Media; IF: immunofluorescence). (B) FACS plots showing MuSCs (black gate) in GAS, DIA, C, ICa, and PCa. (C) Experimental design for panel D. (D) Left: Pax7 expression in freshly isolated cells (scale bar 50 µm); right: quantification of Pax7+ cells plated for 2 h after isolation. (E) Experimental design for panel F. (DM: Differentiation Media). (F) Left: MyHC expression in differentiated cells (scale bar 50 µm); right: quantification of MyHC + nuclei after 72 h in DM.](nihms-1068079-f0004){#F4}
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KEY RESOURCES TABLE

  Reagent or resource                                                             Source                           Identifier
  ------------------------------------------------------------------------------- -------------------------------- -----------------------------------
  Antibodies                                                                                                       
  PE/Cy7 anti-mouse/rat CD29 antibody                                             Biolegend, USA                   Cat\#102221, RRID:AB_528789
  Mouse NCAM-1/CD56 PE-conjugated antibody                                        R&D Systems, USA                 Cat\# FAB7820P
  PE anti-rat CD106 antibody                                                      Biolegend, USA                   Cat\#200403, RRID:AB_2214210
  Alexa Fluor® 647 mouse anti-rat CD45                                            BD Biosciences, USA              Cat\#565465, RRID:AB_2739250
  APC mouse anti-rat CD11b                                                        BD Biosciences, USA              Cat\#562102, RRID:AB_10896148
  CD31/PECAM-1 antibody (TLD) \[Alexa Fluor® 647\]                                Novus, USA                       Cat\# NB100-- 64796AF647
  Anti-Laminin antibody produced in rabbit                                        Sigma-Aldrich, USA               Cat\# L9393, RRID:AB_477163
  Pax7                                                                            DSHB, USA                        Cat\# Pax7-c
  Purified mouse anti-MyoD                                                        BD Biosciences, USA              Cat\#554130, RRID:AB_395255
  Purified mouse anti-Myogenin                                                    BD Biosciences, USA              Cat\#556358, RRID:AB_396383
  MyHC                                                                            DSHB, USA                        Cat\# Mf20-c
  Goat anti-rabbit IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 546   Thermo Fisher Scientific, USA    Cat\# A11035, RRID:AB_2534093
  Goat anti-mouse IgG1 Cross-adsorbed secondary antibody, Alexa Fluor 488         Thermo Fisher Scientific, USA    Cat\# A21121, RRID:AB_2535764
  DAPI solution (1mg/mL)                                                          Thermo Fisher Scientific, USA    Cat\#62248
  Chemicals, Peptides, and Recombinant Proteins                                                                    
  Ham's F-10 Nutrient Mix                                                         Life Technologies, USA           Cat\#11550043
  Horse Serum                                                                     Sigma-Aldrich, USA               Cat\#H1270--550ML
  Collagenase, type II, powder                                                    Life technologies, Gibco®, USA   Cat\#17101015
  Dispase II, powder                                                              Life technologies, Gibco®, USA   Cat\#17105041
  Laminin                                                                         Roche®, Switzerland              Cat\#11243217001
  DMEM, low glucose, Pyruvate                                                     Life technologies, Gibco®, USA   Cat\#11885092
  Fetal bovine serum, qualified, heat inactivated, United States                  Life technologies, Gibco®, USA   Cat\#16140071
  Penicillin-Streptomycin (10000 U/mL)                                            Life technologies, USA           Cat\#15140163
  Pepro Tech Inc human FGF-basic (154 a.a), Recombinant protein, 100ug            Fisher Scientific, USA           Cat\#50398738
  PBS, Ph 7.4                                                                     Fisher Scientific, USA           Cat\#10010023
  Paraformaldehyde, 90%, Acros Organics™                                          Fisher Scientific, USA           Cat\#169650025
  Donor goat serum                                                                Gemini Bio-Products, USA         Cat\#100--109
  Triton X-100                                                                    Sigma-Aldrich, USA               Cat\# X100--500ML
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